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Immune responseAlthough intrastriatal transplantation of fetal cells for the treatment of Parkinson’s disease had shown
encouraging results in initial open-label clinical trials, subsequent double-blind studies reported more
debatable outcomes. These studies highlighted the need for greater preclinical analysis of the parameters
that may influence the success of cell therapy. While much of this has focused on the cells and location of
the transplants, few have attempted to replicate potentially critical patient centered factors. Of particular
relevance is that patients will be under continued L-DOPA treatment prior to and following transplanta-
tion, and that typically the grafts will not be immunologically compatible with the host. The aim of this
study was therefore to determine the effect of chronic L-DOPA administered during different phases of
the transplantation process on the survival and function of grafts with differing degrees of immunological
compatibility. To that end, unilaterally 6-OHDA lesioned rats received sham surgery, allogeneic or xeno-
geneic transplants, while being treated with L-DOPA before and/or after transplantation. Irrespective of
the L-DOPA treatment, dopaminergic grafts improved function and reduced the onset of L-DOPA induced
dyskinesia. Importantly, although L-DOPA administered post transplantation was found to have no detri-
mental effect on graft survival, it did significantly promote the immune response around xenogeneic
transplants, despite the administration of immunosuppressive treatment (cyclosporine). This study is
the first to systematically examine the effect of L-DOPA on graft tolerance, which is dependent on the
donor-host compatibility. These findings emphasize the importance of using animal models that ade-
quately represent the patient paradigm.
 2016 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
There has been a longstanding debate regarding the potential
toxicity of the mainstay therapy for the neurodegenerative move-
ment disorder Parkinson’s disease (PD), L-DOPA. It has been
hypothesized that the drug may impact on the development of
the disease by hastening or preventing nigral degeneration in PD
patients (Quinn et al., 1986; Diamond et al., 1987; Rajput et al.,
1997; Fahn et al., 2004). While studies suggest it is not clinically
relevant to disease progression, in vitro studies have demonstrated
that dopaminergic neurons in culture are vulnerable to the oxida-
tive damage caused by L-DOPA (reviewed by Olanow (2015)). The
possibility of toxicity however becomes particularly relevant whenlooking at curative or cell replacement strategies for the treatment
of PD.
Fetal cell transplantation of dopaminergic neurons into the
caudate putamen was first trialed in 1989 (Lindvall et al., 1990b).
Having shown encouraging results in preclinical studies and
open-label clinical trials, US-led double-blind placebo controlled
studies failed to demonstrate consistent benefit from the graft
(Lindvall et al., 1990a; Kordower et al., 1995; Hauser et al., 1999;
Hagell and Brundin, 2001). Furthermore these studies, alongside
the retrospective video analysis of the London-Lund-Marburg open
label study, blew the field into disarray with the discovery of motor
side effects persisting after the withdrawal of L-DOPA, now termed
graft-induced dyskinesias (GID) (Hagell et al., 2002; Olanow,
2003). In the search to understand inconsistency in
transplant efficacy and the source of the motor side effects, it is
important to consider factors that are present in patients but
absent in models of transplantation in PD (generally the
6-hydroxydopamine (6-OHDA) lesioned rat). In this context,
L-DOPA toxicity may be of greater relevance as, at the early stageic graft
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ble to the effects of pulsatile dopamine flux. The majority of trans-
plant recipients will have been on L-DOPA medication for some
time prior to transplantation and will remain on it for a significant
period post transplantation, as the graft matures enough to sup-
port effective dopamine function.
Preclinical studies have reported contradictory findings: some
researchers have described failure of the graft to thrive under
L-DOPA treatment (Yurek et al., 1991; Steece-Collier et al., 2009)
while others found no detrimental effect of the treatment on the
survival of grafted dopaminergic cells or their functional efficacy
(Blunt et al., 1990, 1991, 1992; Adams et al., 1994). Nonetheless,
the role of L-DOPA administration pre- and post-transplantation
has not been investigated experimentally in a systematic manner.
Furthermore, most of these papers have used ventral mesen-
cephalon (VM) harvested from the same strain of rat as the hosts,
in order to avoid a graft-induced immune response. While simpli-
fying the model, this has again neglected a factor, which is critical
when considering the transplantation of patients. To the best of our
knowledge, only one paper has thus far combined non-syngeneic
VM transplants and L-DOPA treatment (Soderstrom et al., 2008).
In that paper, L-DOPA was administered to all groups with the
focus being to explore the impact of inflammation on the synaptic
reorganization occurring the presence of L-DOPA. The study was
however not designed to compare the impact of L-DOPA treatment
pre- and post- transplantation in a systematic manner.
In determining the effect of L-DOPA on transplanted fetal
dopaminergic precursors it is therefore paramount to apply this
technique in an improved simulation of ‘real world’ conditions.
The use of syngeneic tissue does not trigger a significant immune
response in rodents. Patients receive pooled allogeneic tissue from
several donors and post-mortem analysis performed on trans-
planted patients has illustrated that, even in well surviving grafts,
there are infiltrating B- and T-lymphocytes in the grafted putamen
indicative of an inflammatory host response in the graft (Kordower
et al., 1997). Human genetic diversity is such that, an allograft
paradigm is insufficiently aggressive to model the immunogenicity
that would be associated with transplanting pooled tissue coming
from multiple donors, as is the case in fetal transplantation for
Parkinson’s disease. Consequently using a donor from a closely
related species (e.g. mouse into rat), termed a concordant xeno-
graft, reproduces many aspects of the humoral response observed
in transplants for MHC-mismatched allotransplants and would be
a more appropriate animal model (Sanchez-Mazas, 2007). This idea
has already been used in primates in whom concordant xenografts
are used to model human allotransplantation (Michler et al., 1996).
This provides a more representative model of the pooled
unmatched allograft used to treat PD, than those models used pre-
viously. The present study was therefore designed to specifically
address the hypothesis that L-DOPA may impact upon graft sur-
vival and function in an immunologically incompatible graft. This
paradigm is as akin to transplantation conditions in patients as
possible, assessing the survival and function of allogeneic and
xenogeneic VM grafts while subject to different L-DOPA adminis-
tration regimes.2. Materials and methods
2.1. Experimental design
122 female Sprague Dawley rats were unilaterally lesioned
using 6-OHDA HBr and split into balanced experimental groups
based on the severity of motor impairment following lesion as
evaluated by amphetamine-induced rotations, cylinder, vibrissae
and stepping tests. The animals were chronically treated withPlease cite this article in press as: Breger, L.S., et al. Influence of chronic L-DOPA
in a rat model of Parkinson’s disease. Brain Behav. Immun. (2016), http://dx.dsaline or L-DOPA for 8 weeks (phase I: daily for 4 weeks then every
other day) before receiving either: an allograft, a xenograft or sham
surgery. Animals receiving xenotransplants were treated daily
with cyclosporine A (CSA) to avoid rapid rejection of the graft
and better mimic the human conditions. In contrast, allografted
animals did not receive any immunosuppressive treatment, as allo-
grafts are usually well tolerated in rats. Moreover, this would allow
a full immunological response to be observed, should the presence
of L-DOPA have an impact. All animals were treated again either
with L-DOPA or saline for another 8 weeks following grafting
(Fig. 1, phase II: daily for 4 weeks then every other day). Dyskine-
sias were assessed once a week during the treatment phases I and
II, both ‘on’ and ‘off’ L-DOPA (Scale B, as described in Breger and
colleagues (2013)). After 2 weeks to allow complete washout of
the drug, motor test were repeated. At the end of the experiment
all animals were transcardially perfused with 1.5% paraformalde-
hyde (Torres et al., 2006).
To verify that there was no overt behavioral consequence of, or
interaction between chronic CSA treatment on L-DOPA-induced
dyskinesia, a supplementary experiment was carried out. 16
female Sprague Dawley received unilateral 6-OHDA lesions and
were selected based on the results of the amphetamine-induced
rotation score. They were then separated in 2 groups: 1) treated
daily with L-DOPA and CSA (n = 8), 2) treated daily with L-DOPA
only (n = 8). Abnormal involuntary movements (AIMs) were scored
twice a week, for 4 weeks (L-DOPA 6 mg/kg) and then once a week,
for 2 weeks (L-DOPA 12 mg/kg), rotational behavior of the rats was
recorded concomitantly.2.2. Animals and materials
Sprague Dawley rats (experiment 1: n = 122 and experiment 2:
n = 16; Harlan, UK) weighing 200–220 g at the start of the experi-
ment were housed 2–4 per cages with ad libitum access to food and
water. The experiments were approved by the Cardiff University
AWERB and carried out in accordance with the UK guidelines for
the care and use of experimental animals under Home Office
License No 30/3036 and European Communities Council Directive
(2010/63/EEC). 6-OHDA, L-DOPA and benserazide were obtained
from Sigma Aldrich, UK; cyclosporine (250 mg/5 ml) was obtained
from Sandoz Pharmaceuticals, UK. Four animals were excluded
from the first experiment due to poor heath, unrelated to the
experimental treatments.2.3. Surgery
2.3.1. 6-Hydroxydopamine lesion
6-OHDA was used to create hemi Parkinsonism in rats. The
toxin was delivered directly into the right medial forebrain bundle
(MFB), which contains the dopaminergic nigrostriatal pathway.
Selective targeting of this site allows near total depletion of nigros-
triatal dopaminergic neurons as described by Torres et al. (2011).
Briefly, the rats were anaesthetized with 2–3% Isoflurane (IVAK,
UK) in a 2:1 O2/NO2 mix and received an infusion of 3 ll of a
30 mM solution of 6-OHDA.HBr (Sigma, UK) containing 0.03% acid
ascorbic into the right nigrostriatal pathway at the following coor-
dinates AP 4.0 mm from bregma; ML +1.3 mm from midline; DV
7.0 mm below dura, with the nose-bar set at 4.5 mm below the
interaural line. The cannula remained in place for 3 min following
injection. Postoperatively, animals were sutured and received a
5 ml injection s.c. of 0.9% sodium chloride containing 4% glucose
for hydration and 10 ll of analgesic (5 mg/ml Meloxicam, Boehrin-
ger Ingleheim, Germany). Post-mortem analysis confirmed that all
animals had greater than 95% loss of tyrosine hydroxylase (TH)
positive cells in the right substantia nigra (no significant differencetreatment on immune response following allogeneic and xenogeneic graft
oi.org/10.1016/j.bbi.2016.11.014
L-DOPA or Saline injections 
Grafting Perfusion 
6-OHDA 
Lesion 
Phase I Phase II 
Week     -4                 0      1                         8                         16          18                    21   
Motor Tests 
Treatment  N= Phase I Graft  type Phase II 
Sham 
SS   6 Saline Sham Saline 
SL   8 Saline Sham L-DOPA 
LS   8 L-DOPA Sham Saline 
LL   8 L-DOPA Sham L-DOPA 
Allograft 
SS 10 Saline Rat VM (E14) Saline 
SL   11* Saline Rat VM (E14) L-DOPA 
LS 12 L-DOPA Rat VM (E14) Saline 
LL 12 L-DOPA Rat VM (E14) L-DOPA 
Xenograft
SS 10 Saline Mouse VM (E12) Saline 
SL   10* Saline Mouse VM (E12) L-DOPA 
LS   11* L-DOPA Mouse VM (E12) Saline 
LL 12 L-DOPA Mouse VM (E12) L-DOPA 
a 
b
Fig. 1. Experimental design. (a) Timeline of the study. (b) Treatment and transplantation received by the animals for each group. The group were named after the treatment
they received in treatment phase 1 and 2: S = saline, L = L-DOPA thus, SS group received saline in treatment phase 1 and 2, SL group received saline in treatment phase 1 and
L-DOPA in treatment phase 2, LS received L-DOPA in Treatment phase 1 and saline in treatment phase 2 and LL received L-DOPA in treatment phase 1 and 2. *These groups
originally numbered 12 animals but some developed tumors unrelated to the experiment, so had be removed from the study.
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p = 0.4439, data not shown).
2.3.2. VM transplant
According to a previous study, the optimal embryonic stage for
mouse VM transplantation is 12 days post-copulatory (Torres et al.,
2007), corresponding to Carnegie stage 16, similarly achieved at
14 days post-copulation in rats (Butler and Juurlink, 1987). Time-
mated pregnant female rats (for allograft: E14 Wistar rats) or mice
(for xenograft: E12 CD1 mice) were obtained commercially (Har-
lan, UK) and terminally anesthetized by intra-peritoneal (i.p.)
injection of 150 mg/kg Pentobarbital (Merial, UK). The fetal brains
were extracted after decapitation and VM were dissected in Hanks’
balanced salt solution (HBSS, Invitrogen, UK). The dissected pieces
were prepared using a common dissociation protocol (Bjorklund
et al., 1983; Torres et al., 2007). Briefly, VM were pooled in trypsin
solution: 0.1% trypsin and 0.05% DNAse (Sigma, UK) in Dulbecco’s
minimum Eagle medium (DMEM, Invitrogen, UK) at 37 C for
10 min, then incubated an extra 10 min in trypsin inhibitors
(Sigma, UK). After a wash in DNAse 0.1% in DMEM medium, VM
were broken into small cells clusters by mechanic dissociation
using gentle pipette trituration. The solution was centrifuged at
2000 rpm/min for 3 min and the number of cells was counted
using a haemocytometer slide. After centrifugation, the pellet
was suspended in an adequate volume of DMEM 0.1% DNAse to
obtain a concentration of 100,000 cell/ll and loaded into a 10 ll
Hamilton syringe. 2 ll of the cell suspension were injected over
2 min into the dopamine depleted striatum of anaesthetized ani-
mals, at the following coordinates: AP: +0.5 mm; ML: 2.5 mm;
DV: 5.0 mm and 4.0 mm (1 ll at each depth) with the nose-Please cite this article in press as: Breger, L.S., et al. Influence of chronic L-DOPA
in a rat model of Parkinson’s disease. Brain Behav. Immun. (2016), http://dx.dbar set at 4.5 mm allowing a flat head. The syringe was left in
place for an additional 3 min for diffusion before being retracted.
Animals transplanted with xenogeneic tissue received cyclosporine
A injections (50 mg/kg i.p.) daily from the day preceding surgery as
immunosuppressant treatment.
2.4. Behavior tests
2.4.1. Amphetamine-induced rotations
The extent of nigrostriatal dopamine depletion induced by the
6-OHDA lesion was evaluated 4 weeks post-surgery, based on the
net ipsilateral rotational behavior induced by administration of
d-Amphetamine (2.5 mg/kg in 0.9% saline i.p., Sigma, UK). The ani-
mals were placed in Perspex bowls and harnessed to automated
rotometers based on the design of Ungerstedt and Arbuthnott
(1970) and the net rotations were recorded over 90 min. Rats were
considered adequately lesioned and used for further study if they
performed at least the equivalent of an average of 6 full turns
per minute (Torres et al., 2011). The same process was used
post-transplantation in order to monitor the functional efficacy
of the graft.
2.4.2. Vibrissae test
The rats were held in a way that allowed the forelimbs to move
freely when the torso and hind limbs were supported and moved
upward from under the bench, allowing the whisker on the tested
side to gently brush the edge of the table. This should induce an
automatic limb placing response on the test side of an intact ani-
mal (Fleming and Schallert, 2011). This test was performed 10
times on each side in order to obtain a percentage estimate oftreatment on immune response following allogeneic and xenogeneic graft
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lesion and after grafting) the whole test was repeated 3 times for
each animal and the mean number of accurate placements across
all tests was calculated.
2.4.3. Stepping test
This task evaluates the ability of the rat to adjust a weight bear-
ing forepaw in response to movement along a flat surface. The rats
were held above a flat bench allowing only one forelimb to touch
the surface of the table bearing weight (the body weight was lar-
gely supported by the experimenter but some weight given to
the paw). The rat was moved laterally in both forehand and back-
hand directions across 1 m of bench over a period of 10 s and the
number of adjusting steps made by the paw was counted for each
forelimb when moved. This test was repeated 3 times at each time
point (before lesion, after lesion, after grafting).
2.4.4. Cylinder test
The rats were placed in a Perspex cylinder (height: 33.5 cm,
diameter: 19 cm) and video recorded. The cylinder was placed
between two mirrors to allow scoring when the rats were back
to the camera. The number of forelimb touches made by each
paw, out of the first 20 touches performed on the cylinder wall,
was counted. Performance in the cylinder test was used to assess
the extent of the lesion and split the animals evenly amount the
groups before treatment and surgery. All of the above behavior
tests were carried out by an experimenter blind to the treatment
of the animals.
2.4.5. Dyskinesia and stereotypic behavior
L-3,4-Dihydroxyphenylalanine (L-DOPA) methyl ester HCl
10 mg/kg and 15 mg/kg of benserazide HCl, dissolved in 0.9% saline
was administered i.p. daily. Dyskinesias were assessed once a
week, both in the presence and absence of L-DOPA treatment using
an AIM rating scale (scale B) and a stereotypic rating scale as
described in a previous study (Breger et al., 2013).
2.5. Immunohistochemistry
Upon completion of all behavioral tests, all animals were killed
under general barbiturate anesthesia (Pentobarbital, 150 mg/kg
i.p.) by transcardial perfusion with 0.2 M buffered saline followed
by 1.5% paraformaldehyde (PFA), the brains removed, and post
fixed in PFA and immersed in 20% buffered sucrose until they sank
(this protocol has been refined and validated in our laboratory see
Torres et al., 2006). The brains were then cut on a freezing sledge
microtome at 40 lm and sections collected in 12 parallel series.
3,30-Diaminobenzidine tetrahydrochloride hydrate (DAB, Sigma,
UK) immunohistochemistry staining was performed as previously
described (Torres et al., 2007), using the following antibodies
anti-TH (AB152, Millipore, 1:2000); anti-CD45, anti-CD4 and
anti-CD8 (MCA48GA, AbD Serotec, 1:500); anti-Ox42 (MCA275G,
AbD Serotec, 1:2000), anti-CD68 (MCA341R, AbD Serotec, 1:100),
anti-glial fibrillary acidic protein (GFAP) (Z0334, Dako, 1:1000),
anti-interleukin-1 beta (IL1b), anti-tumor necrosis factor (TNFa),
anti-interferon gamma (IFNc) (Neoscientific, A1112, A0242,
A11534, 1:200), anti-rabbit IgG (BA-1000, Millipore, 1:200), anti-
mouse IgG (BA-2001, Vector, 1:200). The slides were allowed to
dry at room temperature over night before being dehydrated and
delipidated in a succession of ethanol and xylene solutions. They
were then cover-slipped with distyrene plasticizer and xylene
(DPX). The experimenter was blind to the experimental groups in
assessment of the histology. TH+ cell bodies were counted on a
Leica light microscope (20) for all sections from a 1 in 12 series
through the rat striatum and the total number of dopaminergic
cells was estimated using the Abercrombie method (Hedreen,Please cite this article in press as: Breger, L.S., et al. Influence of chronic L-DOPA
in a rat model of Parkinson’s disease. Brain Behav. Immun. (2016), http://dx.d1998). TH + fiber outgrowth was measured by counting the num-
ber of intersection of fibers on a 10  10 square grid (each square
500 lm2; magnification: 20) located immediately at the graft
host border (periphery) or in the center of the graft (center).
Ox42 cells were counted within 3 frames (572  429 lm; magnifi-
cation: 20), one placed in the middle of the graft and two at the
transplant-host border. Leukocyte counts were carried out using an
automated stereology microscope (Olympus BX50) and a PC-based
image analysis software (Olympus C.A.S.T grid system version 1.6).
The whole striatum was outlined (4) and the enclosed area was
measured by the software. Sections within the selected striatal
area were sampled randomly and CD45 + cells were counted
within a regular series of 286  214 lm window (40). The total
number of cells was estimated using the following formula:
N = R{n  (A/a)}  F  T/(T + H) where n = number of cells
counted, A = inclusion area (striatum), a = total sampling area,
F = frequency of the sections (12), T = thickness of the sections
(40 lm) and H = mean diameter of the cells. The surface area of
the blood vessel was estimated by taking pictures of the sections,
stained for Reca-1 (10), on a Leica DMRBE microscope and ana-
lyzing them with ImageJ software (version 1.45, National Institutes
of Health, USA). The pictures were converted in 8-bit black and
white pictures and the threshold was adjusted to avoid back-
ground noise, before the stained area was measured by the soft-
ware and used as a measure of blood vessel area.2.6. Statistical analysis
Although the nature of dyskinesia rating data is ordinal, non-
parametric tests do not permit the analysis of interactions between
the different key factors of experimental interest (Times, Type of
treatment, Immunological transplantation barriers) as is required
for the factorial design used in all experiments. Therefore, since
1) the categories of dyskinesia rating are strictly interval and
monotonic 2) inspection of the data indicated that the scores were
well distributed between the different categories and 3) analysis of
variance is recognized to be extremely robust to derivation of the
data from the normality of distribution, that is the basis of the
underlying mathematics (Box, 1953), parametric two- and three-
factor split plot ANOVA was used for all analyses, with Newman-
Keuls and Sidak’s post hoc tests as appropriate to determine the
locus of specific significant effects.3. Results
3.1. L-DOPA treatment does not affect the survival or the function of
the graft
Graft survival was determined by counting dopaminergic TH
positive cell bodies present in the striatum. Both allogeneic and
xenogeneic transplanted cells survived well (1675 ± 133 and
1603 ± 193 average of TH positive cell bodies respectively). These
data are comparable to previous study that reported a survival of
syngeneic transplanted VM ranging between 0.7% and 1.5%
(Steece-Collier et al., 2009; Heuer et al., 2013; Tamburrino et al.,
2015). There was no significant difference between the numbers
of TH positive cell bodies in the allogeneic versus xenogeneic
transplanted groups (Fig. 2a–d; F2,115 = 34.33; Sidak’s post hoc test
p = 0.999). The allogeneic transplant seems to better innervate the
host striatum than the xenograft, however, the difference was not
significant. Moreover, L-DOPA treatment had no impact on the
innervation (mean graft to host fiber density allograft SS:
52.9 ± 9.0; allograft LL: 64.33 ± 8.6; xenograft SS: 35.0 ± 6.0; xeno-
graft LL: 34.36 ± 5.3). Similarly, L-DOPA regime (SS, SL, LS, LL) had
no impact on the survival of transplanted cells (Fig. 2a–d;treatment on immune response following allogeneic and xenogeneic graft
oi.org/10.1016/j.bbi.2016.11.014
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Fig. 2. Graft survival and function. (a) The data represent the total number of tyrosine hydroxylase (TH) positive cell bodies present in the transplanted striatum. (b–d)
Pictures are representative of each type of graft (these 3 pictures have been selected from the L-DOPA naïve group SS but all the grafts looked similar within each transplant
group). (e) Amphetamine-induced rotational behavior. The data represent the relative number of ipsilateral turns performed over 90 min, 10 weeks after transplantation. All
data are presented as mean ± SEM for each group, total n = 118.
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L-DOPA pre and/or post graft did not affect the survival of
dopaminergic neurons, regardless of immunogenic compatibility.
The functionality of the transplant was assessed 10 weeks post-
transplantation by recording the total number of amphetamine-
induced rotations performed by the rats. Following lesions, all
animals exhibited approximately 6–11 ipsilateral rotations per
min, which continued for the duration of the 90 min test
(941.5 ± 22.5 net ipsilateral turn on average). In the absence of a
transplant, the animals showed an increase in amphetamine-
induced rotations over the subsequent tests (up to 25% increase
by 18 weeks post lesion). In contrast, both groups of animals trans-
planted with VM tissue showed a significant reduction in rota-
tional behavior (76% and 83% reduction after allogeneic and
xenogeneic transplant respectively) compared to the sham treated
group (Fig. 2e; F2,115 = 49.51; Sidak’s post hoc test p < 0.0001).
However, there was no difference between the groups grafted with
allogeneic (rat) or xenogeneic (mouse) tissue (p = 0.646), or
between the different treatments within each transplantation
group (Fig. 2e; treatment main effects F3,106 = 0.392; p = 0.759;
graft and treatment interactions F6,106 = 0.718; p = 0.636). No
graft-induced or amphetamine-induced post-graft dyskinesias
were observed in any group.
Finally, the impact of a dopaminergic intra-striatal graft on
motor function was assessed by counting the number of lateralized
steps and vibrissae-elicit limb placement performed on the con-
tralateral side to the lesion. No motor function recovery was
observed in any of the groups, regardless of the type graft or treat-Please cite this article in press as: Breger, L.S., et al. Influence of chronic L-DOPA
in a rat model of Parkinson’s disease. Brain Behav. Immun. (2016), http://dx.dment that the rats received (Table 1; vibrissae test F6,106 = 1.248;
p = 0.288; stepping test backhand F6,106 = 0.285; p = 0.943; step-
ping test forehand F6,106 = 0.292; p = 0.939).3.2. L-DOPA-induced motor dysfunctions
None of the saline treated control group (SS, in each transplan-
tation set) displayed rotational behavior, beyond spontaneous ipsi-
lateral rotations, which are commonly observed in 6-OHDA
lesioned animals (Table 1, grey). As expected, they also failed to
develop any AIMs. Since all animals obtained a consistent null
score, the SS AIMs results are not presented and were excluded
from statistical analyses. All L-DOPA treated groups (SL, LS, LL) pro-
gressively developed AIMs; from the first day of L-DOPA treatment
(Fig. 3). Dyskinesia scores rapidly increased and reach a ceiling
2–3 weeks after initiation of the treatment in each group. Interest-
ingly, delaying the onset of L-DOPA to phase II, in the sham trans-
plantation group (SL), resulted in more severe dyskinesias than
when the animals received the drug from phase I (Sham group:
Fig. 3a–c; SL: 116.5 ± 2.4, LS: 62.4 ± 2.1, LL: 60.1 ± 3.8). However,
both allo- and xenogeneic fetal dopaminergic cells transplant,
prior to the initiation of L-DOPA treatment in phase II, prevented
exacerbation of AIMs (Fig. 3d, g; Allograft SL: 54.4 ± 4.3; Xenograft
SL: 62.9 ± 4.1). Rats receiving chronic treatment with L-DOPA
throughout (before and after grafting, LL, Fig. 3c, f, and i) showed
a decreasing trend in AIMs scores following VM transplantation.
Nonetheless, this was only significant in the xenografted group,treatment on immune response following allogeneic and xenogeneic graft
oi.org/10.1016/j.bbi.2016.11.014
Table 1
Behavioral tests (vibrissae and stepping) were conducted after lesion and again 10 weeks after grafting (week 18). Data are presented as Means ± SEM. One-way ANOVA analysis
of variance comparing results after lesion and after grafting, all n.s. 1percentage of left limb responses to vibrissae stimulation, 2the number of steps performed with the left
forelimb while moving the animal in the forehand or backhand direction. Stereotypy score and rotational behavior (week 20) were significantly lower in the saline groups (SS,
grey) regardless of the type of transplant. No difference was found between the 3 other treatment groups treated with L-DOPA (SL, LS, LL).
Group Vibrissae1 Stepping (backhand)2 Stepping (forehand)2 Stereotypic L-DOPA induced
Post lesion Post graft Post lesion Post graft Post lesion Post graft Behavior Rotations
Sham SS 15.0 ± 2.2 9.3 ± 4.9 7.7 ± 1.8 8.5 ± 1.5 2.7 ± 0.7 3.3 ± 0.9 0.33 ± 0.33 28.79 ± 8.84
SL 15.3 ± 5.2 14.9 ± 4.6 9.8 ± 1.4 8.1 ± 0.9 3.0 ± 1.2 2.1 ± 1.2 11.00 ± 0.65 497.1 ± 96.03
LS 14.1 ± 3.7 9.1 ± 3.3 8.6 ± 1.9 9.1 ± 1.7 3.3 ± 1.5 1.4 ± 0.3 11.12 ± 1.65 432.96 ± 195.70
LL 17.5 ± 4.9 14.5 ± 5.1 9.1 ± 1.6 5.5 ± 1.2 2.4 ± 0.6 1.9 ± 0.7 9.62 ± 1.85 470.7 ± 132.40
Allograft SS 14.4 ± 2.9 15.4 ± 5.6 8.1 ± 0.9 9.3 ± 1.1 2.7 ± 0.4 2.6 ± 0.4 0.40 ± 0.40 38.53 ± 17.95
SL 14.2 ± 2.5 13.8 ± 4.1 7.4 ± 0.6 7.6 ± 1.4 2.3 ± 0.8 1.5 ± 0.6 8.45 ± 1.89 126.9 ± 50.53
LS 16.8 ± 3.2 16.7 ± 6.9 8.7 ± 1.3 9.4 ± 1.1 2.5 ± 0.6 1.5 ± 0.3 7.91 ± 1.29 264.6 ± 111.6
LL 14.5 ± 2.9 21.7 ± 6.1 8.5 ± 1.0 8.6 ± 1.1 3.3 ± 0.6 2.8 ± 0.4 10.91 ± 1.51 251.9 ± 70.82
Xenograft SS 14.6 ± 3.2 26.2 ± 7.1 7.9 ± 1.1 6.2 ± 1.4 2.6 ± 0.5 1.7 ± 0.9 0.40 ± 0.27 22.45 ± 6.78
SL 14.9 ± 3.1 23.6 ± 8.0 8.0 ± 1.0 8.1 ± 1.0 2.5 ± 0.6 2.5 ± 0.6 7.70 ± 1.93 31.78 ± 20.66
LS 14.3 ± 3.7 24.4 ± 6.4 8.4 ± 1.6 4.7 ± 1.1 2.8 ± 1.0 2.2 ± 0.6 9.09 ± 1.81 119 ± 42.94
LL 16.1 ± 3.5 19.4 ± 6.4 8.7 ± 1.2 5.5 ± 1.3 3.2 ± 0.6 2.2 ± 0.5 10.08 ± 1.77 107.9 ± 46.39
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Fig. 3. L-DOPA induced-dyskinesias. Average of abnormal involuntary movement (AIMs) scores rated before and after striatal transplantation (dotted line) of rat VM (middle
panel) mouse VM (bottom panel) or sham surgery (top panel). The different treatments for each phase (I and II) are color-coded: white for saline or grey for L-DOPA. Data
presented as mean ± SEM, *p < 0.05 compare to last trial prior-transplant.
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F16,176 = 2.729; p = 0.0007).
L-DOPA-induced rotational behavior was recorded concomi-
tantly. During the final L-DOPA challenge (12 weeks post-
transplantation), the rats that have been grafted with fetal neurons
showed a decreased in contralateral turns when compared to thePlease cite this article in press as: Breger, L.S., et al. Influence of chronic L-DOPA
in a rat model of Parkinson’s disease. Brain Behav. Immun. (2016), http://dx.dsham surgery groups (Table 1; F2,106 = 11.35; p < 0.0001). No signif-
icant difference was found between the two types of graft
(p = 0.226) or the 3 different regimes of L-DOPA administration
(SL, LS, LL, main effect of Treatment: F2,92 = 1.718; p = 0.186).
Regarding stereotypic behavior, animals treated only with sal-
ine remained mostly inactive, as reflected by a mean stereotypictreatment on immune response following allogeneic and xenogeneic graft
oi.org/10.1016/j.bbi.2016.11.014
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however, exhibited similar stereotypic-like behaviors following L-
DOPA administration, which increased over time. Neither the
treatment regime, nor the type of graft had an impact on L-
DOPA-induced stereotypies (week 20, Table 1, main effect of Treat-
ment: F3,106 = 23.97, p < 0.001; of Graft: F3,106 = 0.64; p = 0.53).
3.3. L-DOPA treatment influences immune response
Inflammation and immune response against the graft was eval-
uated using a microglia marker (Ox42) and a leukocyte marker
(CD45). The presence of the graft (regardless of type), generally
increased the number of microglia in the grafted area (Fig. 4a–e,
F2,103 = 9.89, p = 0.0002). An interaction was found between the
type of graft (allogeneic or xenogeneic) and the treatment admin-
istered (F6,103 = 3.36, p = 0.005). Specifically, the xenograft signifi-
cantly increased the number of Ox42+ cells in the transplanted
area. Within the xenograft group, the most significant increaseSham Allograft Xenograft
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(Ox42) of the xenografted area. (f) Total number of leukocytes in the grafted striatum and
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observed in the striatum of xenotransplanted animals, which received L-DOPA through
Please cite this article in press as: Breger, L.S., et al. Influence of chronic L-DOPA
in a rat model of Parkinson’s disease. Brain Behav. Immun. (2016), http://dx.dwas found in the group treated with L-DOPA during both treatment
phases (Fig. 4e, LL) when compared to the other 3 treatment
groups (Fig. 4a; compared to SS and LS: p < 0.0001, SL: p = 0.02).
Representative pictures of the microglia staining in the striatum
of xenotransplanted animals are presented in Fig. 4(b–e).
The number of infiltrated leukocytes in the transplanted stria-
tum was significantly higher in the xenogeneic graft group (Fig. 4f,
F2,103 = 8.89, p = 0.0003, post hoc analysis p < 0.001) but no differ-
ence was found between the sham and the allograft groups neither
was there an effect of L-DOPA treatment in these groups
(F3,103 = 1.81; p = 0.149). To better understand the effect of the dif-
ferent L-DOPA regimes on the xenograft group, this transplant
group was analyzed separately. In the SS group of rats that had
never been exposed to L-DOPA, very few CD45+ cells were
observed (Fig. 4g). In contrast, in all groups that had been treated
with L-DOPA, a consistent increase in infiltrated cells was found
throughout the striatum (Fig. 4h-j). The mean number of
leukocytes infiltrated in the 2 groups that received L-DOPAXenograft
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8 L.S. Breger et al. / Brain, Behavior, and Immunity xxx (2016) xxx–xxxpost-grafting was 3 and 6 times higher than in the SS control group
(Fig. 4f, v23 = 15.18, p = 0.0017). The most striking observation was
the presence of agglomerated leukocytes along the blood vessels,
close to the grafted area, which was seen in some of the rats treated
with L-DOPA post-grafting (Fig. 4i and j). Interestingly, in the same
animals, the Ox42 staining revealed the presence of dense and
aligned microglia, resembling gliosis (microglia scarring,
Fig. 4d and e).
In order to characterize the subtypes of T cells involved in the
lymphocytic immune response, CD4 and CD8 immunostaining
was performed on the brains of the rats grafted with xenogeneic
tissue and treated with L-DOPA before and after grafting (Fig. 4k,
xenograft, LL). The number of CD4 positive cells was higher than
the number of CD8 positive cells (Mann-Whitney test, U = 35,
p < 0.033). Additional immunohistochemical analyses were per-
formed on some animals in the xenotransplanted group to better
characterize the type of immune response promoted by L-DOPA
treatment post-transplantation (Supplementary Fig. 1). Intense
astroglial (GFAP) activation was observed, as expected, with the
additional presence of phagocytic cells (CD68+ cells) inside the
graft and at the graft-host boundary. Some IL1b positive cells were
identified located mainly within the graft itself, whilst the few cells
positive for TNFa or IFNc were found predominantly at the graft-
host boundary.
To evaluate the effect of prolonged exposure to L-DOPA on the
blood vessels and angiogenesis, sections were labeled immunohis-
tochemically using a pan-vascular endothelium marker (RECA-1,
data not shown). No significant difference was found between
the contralateral (left) and ipsilateral (right) hemisphere to the
graft (respectively 237.1 ± 12.3 lm2 and 233.2 ± 12.6 lm2
(F1,40 = 0.73, p = 0.397). Similarly, the treatment did not seem to
have an impact on vascularization of the transplanted striatum
(SS: 231.3 ± 11.8 lm2; LL: 234.8 ± 12.6 lm2). Since no difference
was found between the SS and LL groups in the xenografted ani-
mals (considered to be the two most extreme scenarios), the other
groups were not analyzed (F1,40 = 0.105, p = 0.748).3.4. CSA does not interfere with AIMs development
In a separate experiment, L-DOPA (6 or 12 mg/kg) was adminis-
tered concomitantly with CSA in order to assess potential interac-
tion between the two treatments. As expected, both AIMs and
contralateral rotations increased with L-DOPA dose (Fig. 5, AIMs:
F9,126 = 9.46, p < 0.0001; rotations: F9,126 = 16.38, p < 0.0001). Ani-
mal receiving CSA developed similar level of L-DOPA-induced side
effects when compared to animals treated with saline, regardless
of the dose of L-DOPA (AIMs: F1,126 = 0.03, p = 0.875 and rotations:
F1,126 = 0.01, p = 0.921). These data suggest that CSA treatment did
not interfere with L-DOPA treatment.4. Discussion
This study is the first systematic evaluation of the interaction
between drug treatment of Parkinson’s disease, delivered before
and/or after transplant, and the presence of a neuronal graft that
is not immunologically compatible with the host. The results of
this paper reiterate that VM allogeneic (rat) transplant (in absence
of immunosuppression) and xenogeneic (mouse) transplant (in
CSA treated animals) can survive well in the striatum of 6-
OHDA-lesioned rats and produce functional effects, enabling a
reduction of drug-induced motor asymmetry (Blunt et al., 1990,
1992; Gaudin et al., 1990; Olsson et al., 1995; Lee et al., 2000;
Carlsson et al., 2006; Steece-Collier et al., 2009; Tamburrino
et al., 2015).Please cite this article in press as: Breger, L.S., et al. Influence of chronic L-DOPA
in a rat model of Parkinson’s disease. Brain Behav. Immun. (2016), http://dx.dOverall, the beneficial effect of the transplantation in this exper-
iment was limited and no improvement of motor functions, as
assessed by stepping or whisker tests, was observed. This is likely
a result of smaller grafts that were intentionally produced to
enable a clear determination of the positive or negative effects of
L-DOPA. Transplant studies in 6-OHDA rats commonly graft a
higher number of cells (2–10 times more cells) (Dunnett et al.,
1981; Nikkhah et al., 1994; Goren et al., 2005; Torres et al.,
2007) and although it has been shown that transplantation of as
little as 50,000 cells is enough to obtain reduction on the drug-
induced rotation test, motor function recovery appears to require
larger grafts (Bartlett et al., 2004). The low number of transplanted
cells might also explains the fact that, contrary to what has been
reported previously, the rats never developed post-transplant AIMs
‘‘off-drug” (during neither light or dark phases of the light cycle), or
following amphetamine injection (Carlsson et al., 2006; Lane et al.,
2006, 2009; Garcia et al., 2011). However, the grafts were large
enough to impede the development of L-DOPA-induced dyskinesia,
when L-DOPA was initiated post-transplantation. These finding are
in line with Steece-Collier et al. (2009) study and lends itself in
favor of intervening earlier in the disease course, a track which is
being followed by the current EU funded clinical trial with fetal tis-
sue transplantation TransEUro (Moore et al., 2014).
A key finding of this paper, that may have implications for long
term graft survival and function, was that the presence of L-DOPA,
specifically in the xenograft group, heightened the immunological
response. The multifactorial approach used in this paper was vali-
dated by pathology very similar to that seen in post-mortem exam-
inations of patients receiving graft material. We found increasedtreatment on immune response following allogeneic and xenogeneic graft
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(CD45+) in the grafted area, including phagocytic cells (CD68+),
in animals transplanted with xenogeneic VM and treated with
L-DOPA post transplantation. Despite good graft survival and fibers
outgrowth, the presence of IL1b positive cells, as well as TNFa and
IFNc in these animals, might hint toward a pro-inflammatory stage
of the immune response, likely to be detrimental to the graft in the
long run. Analysis of the brains of a patient with a well-surviving
18 months old VM transplant similarly reported the presence of
immune cells invading, including phagocytic cells (CD68+) and
lymphocytes T- and B-cells (Kordower et al., 1997). Three to four
years post-transplant, patients who have received longer immuno-
suppressive treatment, showed a mild increase of GFAP or CD68
positive cells (mainly along the needle tracks) (Mendez et al.,
2005). Interestingly, a patient transplanted bilaterally (16 and
12 years before his death) showed GFAP-immunoreactive
astrogliosis on both side of the brain despite the presence of a good
dopaminergic grafts, while another patient (at 22-years post-
transplant), showed no sign of astrogliosis and had no remaining
TH positive transplanted cells (Kurowska et al., 2011). All together,
these data suggest that even though dopaminergic grafts seem to
survive quite well in presence of infiltrating immune cells, at least
for the first decade, they might eventually succumb to the host
defense system. It is noteworthy that in a recent analysis of a
patient’s brain 24 years after fetal transplant, very good survival
of the dopaminergic cells was found with limited immune
response (as assessed by IBA-1 and CD68 staining). Pertinent to
this study, the patient did exceedingly well post-transplantation
such that his medication steadily reduced and benefited from a
complete withdrawal of L-DOPA two and half years after trans-
plantation, while he remained under immunosuppression for few
years after that (Li et al., 2016).
These observations of interactions between graft and drug
treatment raise interesting clinical and biological questions of crit-
ical relevance to the future development of non-autologous cell
transplantation for neurological conditions, and for the preclinical
models that are used to promote that translational goal. The
mechanism by which chronic L-DOPA treatment, administered
post-transplantation, increases the immune response around
non-compatible grafts remains unclear and but we have consid-
ered three hypotheses: 1) interference of L-DOPA with the action
of CSA immunosuppressive treatment, 2) a direct action of
L-DOPA on immune cell proliferation and/or activation, or 3)
induction of blood-brain barrier impairment directly allowing an
influx of immune cells. Competition for transport of L-DOPA and
CSA through the intestinal wall and/or at the blood-brain barrier
level might occur since CSA is transported through the
P-glycoprotein 1, which can also provide a substrate for L-DOPA
to enter both the intestinal lumen and the brain (Saeki et al.,
1993; Vautier et al., 2008). Here we show that rats developed
similar behavioral abnormalities (aka dyskinesia and rotational
behavior) while exposed to L-DOPA, regardless of co-treatment
with CSA, which implies that CSA does not interfere with L-DOPA
penetration into the brain. However, we cannot rule out that
L-DOPA might interfere with CSA transport. Lymphocytes are
known to express TH, DOPA-decarboxylase, as well as DA receptors
and transporters (Santambrogio et al., 1993; Ricci and Amenta,
1994; Ricci et al., 1998; Amenta et al., 1999; Ricci et al., 1999;
McKenna et al., 2002; Cosentino et al., 2007) but even though a
direct action of L-DOPA on immune cells at the periphery could
be hypothesized, it is considered unlikely since L-DOPA is co-
administered with a peripherally acting aromatic L-amino acid
decarboxylase. Finally, L-DOPA treatment and dyskinesias have
been associated with enhanced blood flow and blood vessel per-
meability in the striatum, which could facilitate access of periph-
eral immune cells such as leukocytes, to the brain (Westin et al.,Please cite this article in press as: Breger, L.S., et al. Influence of chronic L-DOPA
in a rat model of Parkinson’s disease. Brain Behav. Immun. (2016), http://dx.d2006; Lindgren et al., 2009; Ohlin et al., 2012). In this study we
found no direct evidence of angiogenesis but we cannot exclude
that modifications at the level of the blood brain barrier have
occurred. Further work is required to establish to what extent each
of these mechanisms plays a key role in the L-DOPA-induced
increased host immune response phenomenon that we observed
in xenogeneic transplanted animals.
Establishing a reliable animal model to study the parameters
influencing the success of cell therapy for PD is a crucial but con-
voluted task. To the best of our knowledge we are the first group
to attempt to replicate much of this multi factorial process. This
has necessitated a thorough and systematic approach, which has
produced some insights into a possible interaction between the
graft, drug therapy and immune system. We have shown here that
L-DOPA treatment, administered post-transplantation, can
increase immune responses despite immunosuppressive treatment
and believe that this should be taken into consideration for further
trials of cell transplantation. With the upcoming development of
stem cell-based therapies (Barker et al., 2015) the question
remains as to whether the outcome would be the same with cells
obtained from alternative sources and whether other common
medications could influence other aspects of graft function and
development.
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